CDK19 and bone neoplasm: The lncRNA NEAT1 acts as a bridge between CYCLINL1 and CDK19 to promote Pol II ser2 phosphorylation, which might represent a new target for the treatment and diagnosis of bone cancer metastasis (Wen S. et al., 2020).